highlight
human
antibodi
zikv
test
mous
model
vitro
neutral
activ
correl
vivo
protect
potent
antibodi
provid
protect
infect
markedli
delay
mortal
summari
zika
viru
zikv
mosquitotransmit
flaviviru
gener
benign
human
howev
emerg
strain
zikv
becom
widespread
caus
sever
preand
postnat
neurolog
defect
urgent
need
prophylact
therapeut
agent
address
investig
six
human
monoclon
antibodi
zikv
epitop
specif
neutral
activ
mous
model
zikv
infect
microcephali
singl
intraperiton
inject
antibodi
convey
distinct
level
adult
utero
protect
zikv
infect
close
mirror
respect
vitro
neutral
activ
one
antibodi
show
potent
neutral
activ
complet
protect
uninfect
mice
markedli
reduc
tissu
patholog
infect
mice
thu
promis
candid
develop
antibodybas
intervent
inform
ration
design
zikv
vaccin
zika
viru
zikv
mosquitotransmit
flaviviru
caus
sever
neurolog
defect
human
li
et
al
identifi
human
monoclon
antibodi
capabl
protect
zikv
infect
relat
diseas
test
mous
model
antibodi
serv
promis
candid
clinic
develop
zikv
recent
widespread
neurolog
deficit
caus
emerg
strain
zika
viru
zikv
caught
world
guard
wikan
smith
zikv
first
identifi
forest
uganda
infect
gener
benign
human
dick
et
al
howev
new
strain
zikv
far
virul
caus
rang
clinic
anomali
rasmussen
et
al
wikan
smith
notabl
microcephali
congenit
defect
infant
born
mother
infect
zikv
pregnanc
mlakar
et
al
petersen
et
al
rasmussen
et
al
wikan
smith
although
exact
mechan
neuropathogenesi
remain
uncertain
clinic
abnorm
link
aberr
develop
loss
neural
progenitor
cell
npc
cugola
et
al
gabriel
et
al
garcez
et
al
li
et
al
li
et
al
tang
et
al
contemporari
strain
zikv
enhanc
replic
capac
special
tropism
npc
cugola
et
al
dang
et
al
garcez
et
al
li
et
al
tang
et
al
although
type
cell
suscept
tabata
et
al
weisblum
et
al
infect
inhibit
npc
prolifer
differenti
trigger
apoptosi
autophagi
critic
highest
rate
birth
defect
occur
pregnant
mother
infect
first
second
trimest
presum
earli
stage
gestat
npc
greater
suscept
zikv
infect
viral
transfer
across
placent
barrier
mlakar
et
al
petersen
et
al
rasmussen
et
al
wikan
smith
fulli
protect
develop
fetus
intervent
must
occur
period
ideal
prior
infect
marston
et
al
neutral
antibodi
essenti
mediat
immun
viral
infect
burton
hangartn
corti
lanzavecchia
zikv
flavivirus
human
neutral
monoclon
antibodi
target
surfac
envelop
glycoprotein
e
facilit
infect
dejnirattisai
et
al
fernandez
et
al
fibriansah
et
al
heinz
stiasni
magnani
et
al
pierson
diamond
pierson
graham
robbiani
et
al
roger
et
al
sapparapu
et
al
stettler
et
al
wang
et
al
wang
et
al
zhao
et
al
previous
report
panel
monoclon
antibodi
mab
deriv
longitudin
sampl
zikvconvalesc
individu
character
neutral
activ
epitop
specif
develop
timelin
cours
infect
also
report
mous
model
zikv
infect
microcephali
enhanc
specif
neurolog
infect
figur
experiment
design
evalu
prophylact
potenti
six
human
mab
zikv
infect
develop
fetus
mice
timelin
mab
inject
zikv
inocul
infant
deliveri
monitor
complementari
set
clinic
virolog
neuropatholog
outcom
embryon
day
six
mab
test
shown
alongsid
ic
valu
epitop
specif
zikvinocul
fetus
neonat
indic
zikv
red
left
unexpos
indic
zikv
blue
cartoon
mice
includ
zikv
small
larg
indic
red
zikv
larg
indic
blue
size
represent
reflect
potenti
bodi
weight
outcom
mab
test
outcom
monitor
three
litterm
neonat
three
pregnant
mice
b
differ
level
protect
confer
six
mab
shown
number
n
neonat
monitor
surviv
mab
treatment
group
c
bodi
weight
neonat
among
differ
mab
group
zikv
neonat
indic
red
present
percentag
blue
zikv
litterm
group
discern
differ
zikv
zikv
litterm
therefor
shown
singl
redblu
checker
bar
number
neonat
analysi
indic
respect
mab
zikv
red
zikv
blue
legend
continu
next
page
use
contemporari
zikv
asian
strain
model
microcephali
viru
inocul
directli
later
ventricl
fetal
mous
brain
li
et
al
zikv
replic
fetal
brain
preferenti
infect
npc
infect
result
cellcycl
arrest
differenti
defect
larg
number
cell
death
well
clinic
present
microcephali
li
et
al
use
mous
model
zikv
infect
microcephali
analyz
vivo
protect
activ
six
human
mab
compar
find
report
vitro
neutral
activ
measur
plaqu
reduct
neutral
test
prnt
result
offer
compel
evid
vivo
protect
directli
associ
vitro
neutral
one
antibodi
provid
complet
protect
preexposur
treatment
partial
protect
postexposur
therapi
markedli
reduc
tissu
patholog
believ
promis
candid
develop
antibodybas
intervent
inform
vaccin
design
specif
zikv
infect
vivo
protect
correl
vitro
neutral
activ
mab
evalu
compar
protect
potenti
six
repres
human
mab
follow
protocol
highlight
figur
isol
team
two
addit
zikv
domain
iii
diii
specif
mab
isol
other
includ
compar
analysi
robbiani
et
al
zhao
et
al
human
antibodi
middl
east
respiratori
target
middl
east
respiratori
syndrom
coronaviru
merscov
use
neg
control
mab
initi
isol
peripher
b
cell
convalesc
chines
man
acquir
zikv
travel
venezuela
outbreak
specimen
deriv
sequenti
blood
sampl
collect
day
day
day
day
symptom
onset
target
zikv
e
vari
degre
bind
neutral
activ
epitop
specif
exampl
strictli
zikv
specif
demonstr
potent
neutral
activ
measur
prnt
recogn
diii
specif
domain
idomain
ii
didii
comparison
much
less
potent
zikv
crossneutr
member
flaviviru
famili
dengu
viru
serotyp
zikv
envelop
target
either
didii
didiidiii
term
genet
analys
antibodi
demonstr
divers
heavychain
variabl
region
two
fell
immunoglobulinheavi
variabl
ighv
famili
belong
famili
final
belong
famili
respect
test
prophylact
activ
zikv
infect
mgkg
mab
administ
intraperiton
group
three
pregnant
mice
embryon
day
figur
follow
day
develop
litterm
fetus
pregnant
mous
either
left
untouch
zikv
figur
blue
inocul
plaqueform
unit
pfu
zikv
asian
strain
directli
later
ventricl
brain
zikv
figur
red
neonat
close
monitor
deliveri
analyz
complementari
set
clinic
virolog
neuropatholog
outcom
postnat
day
p
surviv
shown
figur
level
protect
confer
differ
mab
vari
consider
clearli
correl
neutral
activ
measur
halfmaxim
inhibitori
concentr
ic
prnt
potent
neutral
mab
confer
complet
protect
surviv
rate
infect
fetus
high
next
potent
howev
confer
partial
protect
median
surviv
day
two
antibodi
isol
other
togeth
rest
mab
isol
us
offer
neglig
protect
virtual
similar
isotyp
control
also
assess
impact
develop
bodi
weight
found
weight
measur
close
correl
neutral
activ
zikv
neonat
treat
potent
mab
weight
gain
similar
zikv
litterm
zikv
neonat
treat
remain
mab
fail
control
zikv
group
greatest
loss
bodi
weight
next
studi
whether
protect
pattern
observ
pregnant
mice
also
occur
nonpregn
mice
administ
mg
mab
isotyp
control
group
four
mice
via
intraperiton
ip
rout
follow
day
anim
challeng
pfu
zikv
asian
strain
via
ip
rout
surviv
rate
bodi
weight
viral
rna
copi
blood
monitor
day
figur
consist
outcom
pregnant
mice
level
protect
nonpregn
mice
correl
antibodi
neutral
activ
measur
halfmaxim
inhibitori
concentr
ic
prnt
figur
exampl
potent
protect
mab
pregnant
mice
provid
complet
protect
nonpregn
mice
surviv
rate
day
challeng
next
potent
protect
confer
partial
protect
median
surviv
day
rest
test
mab
includ
diiispecif
one
isol
other
robbiani
et
al
zhao
et
al
offer
even
lower
level
protect
virtual
ident
isotyp
control
dg
shown
timelin
mab
inject
zikv
inocul
monitor
e
surviv
f
bodi
weight
g
blood
zikv
rna
day
mice
bodi
weight
zikv
rna
whole
blood
deriv
singl
measur
show
distinct
result
among
studi
group
number
anim
use
group
four
data
present
mean
sem
p
p
p
ns
signific
similarli
chang
bodi
weight
measur
followup
also
correl
neutral
activ
zikv
mice
treat
maintain
rel
stabl
bodi
weight
throughout
studi
although
notic
declin
first
blood
sampl
collect
day
figur
contrast
zikv
mice
treat
lost
substanti
bodi
weight
begin
day
postchalleng
anim
treat
remain
mab
sever
rapid
loss
bodi
weight
coincid
clinic
deterior
figur
lastli
zikv
mice
treat
blood
level
viral
rna
indistinguish
measur
uninfect
anim
day
versu
day
versu
challeng
figur
howev
rna
level
measur
mice
averag
log
greater
day
versu
log
greater
day
versu
compar
remain
mab
fail
suppress
viral
replic
measur
zikv
rna
load
day
rang
log
higher
depend
mab
use
figur
taken
togeth
result
demonstr
protect
pattern
mab
similar
pregnant
nonpregn
mice
close
mirror
respect
vitro
neutral
activ
protect
effect
mab
bodi
weight
overal
surviv
mirror
respect
virolog
neuropatholog
outcom
treat
mice
instanc
rna
load
measur
zikv
neonat
treat
suppress
blood
log
copi
per
millilit
brain
log
copi
per
gram
level
indistinguish
zikv
litterm
fact
abl
reduc
zikv
rna
log
blood
log
brain
rel
zikv
group
figur
comparison
equal
effect
suppress
replic
blood
log
copi
per
millilit
moder
protect
brain
log
copi
per
gram
mab
moder
suppress
zikv
replic
blood
log
copi
per
millilit
respect
brain
log
copi
per
gram
respect
none
remain
mab
notabl
suppress
replic
either
blood
brain
tissu
zikv
neonat
treat
mab
high
level
zikv
rna
similar
level
zikv
control
group
significantli
higher
zikv
litterm
figur
importantli
low
level
zikv
rna
associ
healthier
develop
neonat
brain
six
repres
mab
select
indepth
neuropatholog
studi
zikv
mice
treat
either
maintain
normal
brain
growth
structur
notabl
differ
cerebr
size
cortic
thick
later
ventricl
area
zikv
neonat
zikv
litterm
figur
howev
zikv
mice
treat
receiv
moder
protect
fail
provid
protect
low
protect
measur
reduc
cerebr
size
thinner
cortic
enlarg
later
ventricl
zikv
neonat
compar
zikv
litterm
figur
interest
note
especif
human
immunoglobulin
g
igg
level
brain
higher
mice
treat
compar
mab
group
particular
level
mgkg
translat
mgml
zikv
neonat
well
ic
neutral
valu
measur
prnt
wherea
igg
level
mab
group
measur
less
similar
neg
control
pb
group
figur
result
indic
test
mab
abl
transport
across
maternalfet
placent
barrier
primit
bloodbrain
barrier
develop
fetus
saunder
et
al
also
conduct
immunohistochem
analys
brain
section
collect
neonat
group
shown
figur
group
zikvinfect
cell
green
apoptot
cell
red
detect
cortic
either
zikv
neonat
zikv
litterm
matur
neuron
neun
figur
gray
nuclei
dapi
figur
blue
appear
healthi
tightli
pack
structur
throughout
tissu
section
distinct
contrast
larg
number
zikvposit
cell
identifi
throughout
cortic
zikv
neonat
group
high
preval
infect
associ
signific
cell
death
figur
red
degrad
cortic
structur
figur
gray
blue
also
quantit
assess
protect
activ
use
marker
cell
multipl
tissu
section
shown
figur
treatment
zikv
neonat
reduc
zikv
infect
cell
death
level
indistinguish
zikv
litterm
furthermor
group
count
matur
neuron
equival
zikv
neonat
zikv
litterm
figur
howev
zikv
neonat
treat
either
zikvposit
cell
apoptot
cell
count
high
cell
cell
averag
per
squaremillimet
tissu
section
respect
figur
count
matur
neuron
also
significantli
reduc
group
figur
result
support
enhanc
therapeut
activ
cellular
tissu
level
rel
also
offer
explan
impress
vivo
protect
develop
fetus
demonstr
greatest
prophylact
efficaci
zikv
infect
went
evalu
treatment
efficaci
zikv
infect
develop
fetus
specif
litterm
fetus
either
left
untouch
zikv
inocul
pfu
zikv
later
ventricl
zikv
administ
mgkg
ip
pregnant
mice
done
either
day
day
day
later
day
day
later
day
litterm
neonat
close
monitor
deliveri
analyz
outcom
measur
prevent
experi
figur
shown
figur
delay
treatment
day
either
day
day
reduc
surviv
percentag
treatment
day
offer
effect
treatment
median
surviv
day
significantli
higher
mice
treat
either
day
day
day
day
surviv
advantag
confer
treatment
day
correspond
clear
reduct
viral
load
brain
figur
less
damag
cortic
thick
later
ventricl
figur
howev
effect
less
obviou
measur
bodi
weight
red
dot
repres
zikv
blue
dot
repres
zikv
neonat
red
dot
blue
coat
repres
discern
differ
zikv
zikv
litterm
group
number
neonat
mab
analys
indic
group
zikv
red
zikv
blue
g
h
dot
repres
mean
valu
least
two
slice
one
neonat
data
present
mean
sem
p
p
p
ns
signific
blood
serum
viral
load
figur
consid
mous
model
brain
initi
activ
site
viral
replic
expect
antibodi
treatment
effect
would
sensit
immedi
organ
would
appar
effect
organ
bodi
weight
whole
hypothesi
support
immunohistochem
analys
brain
section
deriv
neonat
shown
figur
zikvposit
cell
green
sporad
detect
treatment
group
howev
detect
throughout
cortic
treatment
delay
day
day
greater
level
infect
associ
increas
cell
death
figur
red
cortic
abnorm
figur
gray
blue
particular
tightli
pack
wellorgan
structur
matur
neuron
cortic
becam
loos
connect
disorgan
furthermor
quantit
assess
marker
cell
deriv
multipl
red
dot
repres
zikv
neonat
blue
dot
repres
zikv
litterm
red
dot
blue
coat
repres
discern
differ
zikv
zikv
litterm
group
dot
repres
mean
valu
least
two
slice
one
neonat
analyz
number
neonat
analysi
indic
group
zikv
red
zikv
blue
scale
bar
mm
data
present
mean
sem
p
p
p
tissu
section
support
evid
time
treatment
administr
impact
treatment
efficaci
instanc
zikv
neonat
group
treatment
day
significantli
suppress
number
zikvposit
cell
apoptot
cell
per
squar
millimet
tissu
section
treatment
day
howev
allow
widespread
cell
infect
cell
death
count
high
per
squaremillimet
tissu
section
respect
figur
howev
although
tissu
sampl
three
tempor
treatment
group
show
structur
abnorm
cortic
obviou
reduct
total
number
matur
neuron
figur
treatment
isotyp
control
worst
among
group
sign
figur
evid
therapeut
potenti
zikv
infect
develop
fetus
decreas
surviv
treatment
administr
delay
day
day
day
number
n
neonat
monitor
surviv
indic
bd
treatment
day
day
day
analyz
zikv
neonat
indic
red
zikv
litterm
indic
blue
b
bodi
weight
c
zikv
rna
copi
blood
zivk
rna
copi
brain
number
neonat
analyz
treatment
time
point
indic
group
eg
shown
e
repres
coron
section
neonat
brain
visual
nissl
stain
analyz
f
cortex
thick
g
ventricular
area
f
g
dot
repres
valu
one
slice
total
number
slice
analyz
zikv
day
day
day
respect
number
neonat
analyz
treatment
time
point
indic
group
scale
bar
mm
data
present
mean
sem
p
p
p
ns
signific
protect
figur
result
highlight
critic
role
attenu
diseas
progress
inhibit
cell
infect
death
cellular
tissu
level
furthermor
time
administr
rel
infect
impact
efficaci
treatment
greatest
protect
effect
initi
immedi
infect
report
systemat
analys
prophylact
therapeut
potenti
panel
human
mab
zikv
infect
mous
model
microcephali
nonpregn
mice
show
differ
mab
demonstr
distinct
protect
activ
zikv
infect
major
determin
efficaci
intrins
neutral
activ
singl
ip
inject
pregnant
nonpregn
mice
potent
mab
provid
develop
fetus
adult
anim
complet
protect
zikv
infect
treatment
markedli
reduc
fetal
infect
tissu
patholog
significantli
delay
mortal
thu
promis
candid
develop
antibodybas
intervent
inform
ration
design
zikv
vaccin
two
uniqu
aspect
studi
worth
highlight
one
base
test
mab
deriv
zikv
convalesc
individu
differ
time
point
cours
natur
infect
distinct
neutral
activ
epitop
specif
lineag
ancestri
divers
allow
us
pinpoint
major
determin
protect
mous
model
also
provid
evid
protect
potenti
aris
cours
natur
infect
human
result
clearli
show
neutral
activ
rather
featur
critic
biomark
protect
zikv
infect
although
role
fcmediat
antivir
function
still
need
investig
dejnirattisai
et
al
pierson
graham
sapparapu
et
al
stettler
et
al
among
mab
test
potent
epitop
locat
later
ridg
region
within
diii
e
mab
target
diii
potent
neutral
activ
also
isol
group
deriv
either
infect
human
mice
shown
effect
variou
model
zikv
pathogenesi
fernandez
et
al
magnani
et
al
robbiani
et
al
stettler
et
al
wang
et
al
zhao
et
al
weakli
neutral
mab
also
report
domain
robbiani
et
al
sapparapu
et
al
stettler
et
al
zhao
et
al
would
hard
determin
whether
converg
diii
pure
random
event
whether
diii
epitop
somehow
expos
therefor
access
mab
would
interest
compar
exact
epitop
highli
potent
mab
see
whether
vulner
spot
wide
spread
confin
restrict
region
diii
inform
would
undoubtedli
contribut
understand
immun
recognit
mechan
assist
ration
design
vaccin
zikv
infect
similar
report
diiispecif
mab
isol
late
onset
symptom
day
product
diiispecif
antibodi
becom
preval
total
number
slice
analyz
zikv
day
day
day
b
c
respect
total
number
neonat
analyz
indic
group
data
present
mean
sem
p
p
ns
signific
howev
diiispecif
respons
seem
delay
rel
diiispecif
respons
whether
vaccin
could
induc
prefer
diiispecif
respons
ahead
target
diii
requir
indepth
studi
nevertheless
potent
prophylact
therapeut
activ
demonstr
diiispecif
mab
serv
key
criteria
futur
antibodybas
intervent
zikv
infect
uniqu
aspect
studi
mous
model
microcephali
viru
directli
inocul
later
ventricl
fetal
brain
despit
surgic
sophist
requir
techniqu
model
standard
remark
reproduc
captur
phenotyp
featur
key
zikv
infect
human
li
et
al
wang
et
al
yuan
et
al
direct
inocul
elimin
need
immunedefici
pregnant
mice
allow
control
development
stage
infect
occur
result
pathogenesi
intervent
strategi
evalu
precis
critic
like
stringent
model
brain
infect
test
immedi
protect
activ
mab
inject
site
well
capac
prevent
subsequ
dissemin
throughout
bodi
regard
level
protect
convey
inde
remark
furthermor
direct
inocul
also
allow
studi
immedi
longterm
impact
zikv
infect
develop
fetus
studi
neonat
follow
could
extend
investig
longterm
sequela
zikv
infect
physiolog
cognit
behavior
featur
complementari
exist
model
zikv
infect
initi
earlier
embryon
develop
frequent
associ
fetal
demis
shortli
deliveri
fernandez
et
al
morrison
diamond
sapparapu
et
al
futur
would
interest
test
panel
mab
identifi
earli
infect
model
order
evalu
protect
potenti
conclus
studi
provid
compel
evid
protect
potenti
test
mab
zikv
infect
pregnant
nonpregn
mice
directli
associ
neutral
activ
measur
prnt
potent
neutral
antibodi
demonstr
impress
prophylact
therapeut
activ
therefor
could
serv
promis
candid
antibodybas
intervent
inform
ration
vaccin
design
zikv
infect
previous
report
isol
character
panel
human
mab
longitudin
sampl
zikv
convalesc
individu
show
distinct
neutral
activ
epitop
specif
time
develop
natur
infect
also
report
one
stringent
mous
model
microcephali
contemporari
zikv
asian
strain
inocul
directli
later
ventricl
fetal
brain
li
et
al
present
studi
combin
methodolog
order
evalu
protect
potenti
six
repres
human
mab
zikv
infect
microcephali
use
singl
ip
inject
mab
pregnant
mice
prior
zikv
infect
show
antibodi
convey
distinct
level
protect
develop
fetus
newborn
level
close
mirror
respect
vitro
neutral
activ
potent
neutral
antibodi
test
provid
complet
protect
zikv
infect
preexposur
treatment
partial
protect
postexposur
therapi
measur
markedli
reduc
tissu
patholog
test
mab
target
zikv
e
initi
isol
zikv
convalesc
chines
travel
visit
venezuela
viral
outbreak
detail
neutral
activ
epitop
specif
lineag
ancestri
time
isol
natur
infect
previous
report
two
zikv
diiispecif
mab
isol
other
robbiani
et
al
zhao
et
al
use
compar
analys
mab
human
backbon
manufactur
cell
atcc
transient
transfect
purifi
affin
chromatographi
use
protein
agaros
thermo
scientif
mab
concentr
determin
use
bca
protein
assay
kit
thermo
scientif
previous
isol
human
mab
target
merscov
use
neg
control
jiang
et
al
approxim
mgkg
test
mab
isotyp
control
administ
ip
group
three
pregnant
mice
icr
pregnant
mice
purchas
beij
vital
river
laboratori
anim
technolog
experiment
protocol
procedur
approv
institut
anim
care
use
committe
tsinghua
univers
pregnant
mice
kept
separ
cage
maintain
lightdark
cycl
throughout
experi
test
mab
group
three
pregnant
mice
includ
litterm
neonat
monitor
complementari
set
clinic
virolog
neuropatholog
outcom
surviv
figur
specif
first
second
ii
group
litterm
neonat
sacrif
brain
blood
sampl
immedi
collect
process
frozen
c
use
group
use
measur
viral
load
blood
serum
brain
well
human
igg
brain
group
ii
use
blood
serum
viral
load
brain
size
section
analysi
third
iii
group
litterm
neonat
monitor
bodi
weight
surviv
nonpregn
mice
defici
interferon
ifn
b
g
receptor
mice
purchas
institut
pasteur
shanghai
chines
academi
scienc
mice
bred
maintain
pathogenfre
anim
facil
tsinghua
univers
specif
mg
test
mab
isotyp
control
administ
group
four
mice
via
ip
rout
follow
day
anim
challeng
pfu
zikv
strain
via
ip
inject
monitor
surviv
bodi
weight
viral
rna
copi
blood
day
day
day
challeng
blood
collect
anim
viral
load
measur
microinject
zikv
brain
ml
zikv
asian
strain
genbank
viru
stock
concentr
pfuml
inject
right
side
later
ventricl
embryon
mous
brain
describ
previous
li
et
al
approxim
half
litterm
neonat
inject
zikv
zikv
rest
remain
untouch
zikv
deriv
chines
travel
test
mab
isol
phylogenet
analysi
complet
code
sequenc
indic
tightli
cluster
circul
america
belong
asian
lineag
includ
identifi
french
polynesia
whole
blood
ml
right
brain
neonat
collect
immedi
transfer
eppendorf
tube
contain
lysi
buffer
qiagen
kept
c
use
brain
sampl
weight
homogen
use
stainless
steel
blender
next
advanc
total
rna
homogen
brain
whole
blood
extract
use
rneasi
mini
kit
qiagen
reversetranscrib
cdna
use
iscript
cdna
synthesi
kit
biorad
previous
describ
viral
rna
copi
quantifi
taqman
qpcr
amplif
zikv
envelop
gene
express
log
viral
rna
copi
per
gram
brain
per
millimet
blood
sampl
calcul
standard
curv
sequenc
primer
probe
use
analysi
shown
follow
zikvfccgctgcccaacacaag
zikvr
ccactaa
cgttcttttgcagacat
zikvprob
agcctaccttgacaagcartcagac
actcaa
fam
tamra
neonat
right
brain
collect
immedi
frozen
c
use
frozen
brain
sampl
weight
homogen
stainless
steel
blender
next
advanc
mix
ml
pb
allow
stand
c
hr
test
mab
suspend
pb
collect
centrifug
g
min
quantifi
serial
dilut
applic
elisa
plate
precoat
recombin
fulllength
e
glycoprotein
zikv
previous
describ
bound
mab
detect
use
goat
antihuman
igg
fc
specif
conjug
horseradish
peroxidas
promega
madison
wi
usa
tetramethylbenzidin
tmb
substrat
cwbio
beij
china
mab
level
neonat
brain
calcul
curv
standard
use
correspond
mab
suspend
pb
express
milligram
per
kilogram
microgram
per
millilit
brain
fix
pfa
dehydr
sucros
frozen
tissuefreez
medium
slice
tissu
section
nissl
stain
brain
section
stain
toluidin
blue
min
dehydr
turn
ethanol
twice
hyalin
xylen
min
immunohistochem
stain
section
block
hr
room
temperatur
rt
incub
primari
antibodi
one
night
c
three
round
extens
wash
phosphatebuff
salin
pbst
secondari
antibodi
ad
incub
rt
hr
section
wash
pbst
tissu
section
imag
lsm
carl
zeiss
confoc
microscop
analyz
imari
imagej
describ
previous
li
et
al
antibodi
use
immunohistochem
analysi
abcam
neun
abcam
zikv
serum
deriv
convalesc
patient
nuclei
stain
dapi
invitrogen
experi
involv
pregnant
nonpregn
mice
mice
includ
assess
group
ensur
represent
consist
data
data
analyz
use
softwar
graphpad
statist
evalu
perform
student
unpair
test
data
present
mean
sem
p
p
p
